Drugs / Zilbrix Hib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00473668 | Jun 2007 → Jan 2008 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00678301 Background | Jun 2008 → Nov 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zilbrix-Hib | “The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively.” NCT00678301 ↗ |
| Modality | Vaccine | “DTPw-HBV/Hib vaccine” NCT00473668 ↗ |
| Route | Intramuscular | “administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age” NCT00473668 ↗ |